Found: 40
Select item for more details and to access through your institution.
Vitiligo-specific soluble biomarkers as early indicators of response to immune checkpoint inhibitors in metastatic melanoma patients.
- Published in:
- Scientific Reports, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41598-022-09373-9
- By:
- Publication type:
- Article
New Insights into the Identification of Metabolites and Cytokines Predictive of Outcome for Patients with Severe SARS-CoV-2 Infection Showed Similarity with Cancer.
- Published in:
- International Journal of Molecular Sciences, 2023, v. 24, n. 5, p. 4922, doi. 10.3390/ijms24054922
- By:
- Publication type:
- Article
Integrated Genomics Identifies miR-181/TFAM Pathway as a Critical Driver of Drug Resistance in Melanoma.
- Published in:
- International Journal of Molecular Sciences, 2021, v. 22, n. 4, p. 1801, doi. 10.3390/ijms22041801
- By:
- Publication type:
- Article
Vitiligo-specific soluble biomarkers as early indicators of response to immune checkpoint inhibitors in metastatic melanoma patients.
- Published in:
- Scientific Reports, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41598-022-09373-9
- By:
- Publication type:
- Article
PD-L1<sup>+</sup> neutrophils as novel biomarkers for stage IV melanoma patients treated with nivolumab.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.962669
- By:
- Publication type:
- Article
Altered Frequencies and Functions of Innate Lymphoid Cells in Melanoma Patients Are Modulated by Immune Checkpoints Inhibitors.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.811131
- By:
- Publication type:
- Article
Potential clinical implications of CD4<sup>+</sup>CD26<sup>high</sup> T cells for nivolumab treated melanoma patients.
- Published in:
- Journal of Translational Medicine, 2023, v. 21, n. 1, p. 1, doi. 10.1186/s12967-023-04184-6
- By:
- Publication type:
- Article
IL-6 as new prognostic factor in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab.
- Published in:
- Journal of Translational Medicine, 2023, v. 21, n. 1, p. 1, doi. 10.1186/s12967-023-03971-5
- By:
- Publication type:
- Article
Melanoma-derived soluble mediators modulate neutrophil biological properties and the release of neutrophil extracellular traps.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 10, p. 3363, doi. 10.1007/s00262-023-03493-5
- By:
- Publication type:
- Article
Clinical Categorization Algorithm (CLICAL) and Machine Learning Approach (SRF-CLICAL) to Predict Clinical Benefit to Immunotherapy in Metastatic Melanoma Patients: Real-World Evidence from the Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy
- Published in:
- Cancers, 2021, v. 13, n. 16, p. 4164, doi. 10.3390/cancers13164164
- By:
- Publication type:
- Article
The Ratio of GrzB + − FoxP3 + over CD3 + T Cells as a Potential Predictor of Response to Nivolumab in Patients with Metastatic Melanoma.
- Published in:
- Cancers, 2021, v. 13, n. 10, p. 2325, doi. 10.3390/cancers13102325
- By:
- Publication type:
- Article
ErbB3 Phosphorylation as Central Event in Adaptive Resistance to Targeted Therapy in Metastatic Melanoma: Early Detection in CTCs during Therapy and Insights into Regulation by Autocrine Neuregulin.
- Published in:
- Cancers, 2019, v. 11, n. 10, p. 1425, doi. 10.3390/cancers11101425
- By:
- Publication type:
- Article
Methylation-sensitive restriction enzyme-droplet digital PCR assay for the one-step highly sensitive analysis of DNA methylation hotspots.
- Published in:
- International Journal of Molecular Medicine, 2024, v. 53, n. 5, p. N.PAG, doi. 10.3892/ijmm.2024.5366
- By:
- Publication type:
- Article
Identification of SLC22A17 DNA methylation hotspot as a potential biomarker in cutaneous melanoma.
- Published in:
- Journal of Translational Medicine, 2024, v. 22, n. 1, p. 1, doi. 10.1186/s12967-024-05622-9
- By:
- Publication type:
- Article
Automatic discovery of image-based signatures for ipilimumab response prediction in malignant melanoma.
- Published in:
- Scientific Reports, 2019, v. 9, n. 1, p. N.PAG, doi. 10.1038/s41598-019-43525-8
- By:
- Publication type:
- Article
IL-6 as new prognostic factor in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab.
- Published in:
- Journal of Translational Medicine, 2023, v. 21, n. 1, p. 1, doi. 10.1186/s12967-023-03971-5
- By:
- Publication type:
- Article
Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Could asymptomatic carriers spread the SARS-CoV-2 infection? Experience from the Italian second wave.
- Published in:
- 2021
- By:
- Publication type:
- Letter
A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Clinical Outcome Prediction in COVID-19 Patients by Lymphocyte Subsets Analysis and Monocytes' iTNF-α Expression.
- Published in:
- Biology (2079-7737), 2021, v. 10, n. 8, p. 735, doi. 10.3390/biology10080735
- By:
- Publication type:
- Article
Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study.
- Published in:
- Frontiers in Immunology, 2017, p. 1, doi. 10.3389/fimmu.2017.00386
- By:
- Publication type:
- Article
The MITF/mir-579-3p regulatory axis dictates BRAF-mutated melanoma cell fate in response to MAPK inhibitors.
- Published in:
- Cell Death & Disease, 2024, v. 15, n. 3, p. 1, doi. 10.1038/s41419-024-06580-2
- By:
- Publication type:
- Article
Dendritic cell-derived exosomes (Dex) are potential biomarkers of response to Ipilimumab in metastatic melanoma.
- Published in:
- 2015
- By:
- Publication type:
- Abstract
Analysis of T and NK cells immune response in Ipilimumab treated Melanoma patients.
- Published in:
- 2015
- By:
- Publication type:
- Abstract
Activating PIK3CA mutations coexist with BARF or NRAS mutations in a limited fraction of melanomas.
- Published in:
- Journal of Translational Medicine, 2015, v. 13, n. 1, p. 1, doi. 10.1186/s12967-015-0401-8
- By:
- Publication type:
- Article
Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas.
- Published in:
- Journal of Translational Medicine, 2015, v. 13, n. 1, p. 877, doi. 10.1186/s12967-015-0401-8
- By:
- Publication type:
- Article
Discrepant alterations in main candidate genes among multiple primary melanomas.
- Published in:
- Journal of Translational Medicine, 2014, v. 12, n. 1, p. 1, doi. 10.1186/1479-5876-12-117
- By:
- Publication type:
- Article
Discrepant alterations in main candidate genes among multiple primary melanomas.
- Published in:
- 2014
- By:
- Publication type:
- journal article
Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma.
- Published in:
- Journal of Translational Medicine, 2013, v. 11, n. 1, p. 1, doi. 10.1186/1479-5876-11-202
- By:
- Publication type:
- Article
The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment.
- Published in:
- 2013
- By:
- Publication type:
- Editorial
Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma.
- Published in:
- 2013
- By:
- Publication type:
- journal article
The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment.
- Published in:
- Journal of Translational Medicine, 2012, v. 11, n. 1, p. 1, doi. 10.1186/1479-5876-11-54
- By:
- Publication type:
- Article
Regulatory T cell frequency in patients withmelanoma with different disease stage andcourse, and modulating effects of high-doseinterferon-α 2b treatment.
- Published in:
- Journal of Translational Medicine, 2010, v. 8, p. 76, doi. 10.1186/1479-5876-8-76
- By:
- Publication type:
- Article
Main roads to melanoma.
- Published in:
- 2009
- By:
- Publication type:
- journal article
Upregulated expression of miR-4443 and miR-4488 in drug resistant melanomas promotes migratory and invasive phenotypes through downregulation of intermediate filament nestin.
- Published in:
- Journal of Experimental & Clinical Cancer Research (17569966), 2023, v. 42, n. 1, p. 1, doi. 10.1186/s13046-023-02878-9
- By:
- Publication type:
- Article
Development of a Prognostic Model for Early Breast Cancer Integrating Neutrophil to Lymphocyte Ratio and Clinical-Pathological Characteristics.
- Published in:
- Oncologist, 2024, v. 29, n. 4, p. e447, doi. 10.1093/oncolo/oyad303
- By:
- Publication type:
- Article
Identification of a miRNA-based non-invasive predictive biomarker of response to target therapy in BRAF-mutant melanoma.
- Published in:
- Theranostics, 2022, v. 12, n. 17, p. 7420, doi. 10.7150/thno.77761
- By:
- Publication type:
- Article
Innate Immune Cells in Melanoma: Implications for Immunotherapy.
- Published in:
- International Journal of Molecular Sciences, 2024, v. 25, n. 15, p. 8523, doi. 10.3390/ijms25158523
- By:
- Publication type:
- Article
Frequency of circulating CD8+CD73+T cells is associated with survival in nivolumab-treated melanoma patients.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Characterization of a Novel Polymorphism in PPARG Regulatory Region Associated with Type 2 Diabetes and Diabetic Retinopathy in Italy.
- Published in:
- Journal of Biomedicine & Biotechnology, 2009, p. 1, doi. 10.1155/2009/126917
- By:
- Publication type:
- Article